Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of teclistamab or talquetamab with daratumumab and lenalidomide versus DRd in newly diagnosed transplant-ineligible multiple myeloma
MOH_2024-01-03_013156Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of teclistamab, talquetamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Response and survival-related efficacy assessment and Sustained MRD-negative complete response. Started Dec 2023; status: recruiting.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2024-01-03_013156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-03_013156.